Coamplification of Myc/Pvt1 and homozygous deletion of Nlrp1 locus are frequent genetics changes in mouse osteosarcoma
暂无分享,去创建一个
L. Donehower | P. Rao | J. Yustein | T. Man | N. Rainusso | Shuying Zhao | Vishnupriya J. Borra | Alexander Yu | D. Fuja | M. Trucco | Wendy A Allen-Rhoades | Yi‐Jue Zhao | Laura Satterfield | Yi-jue Zhao
[1] L. Donehower,et al. NKD2, a negative regulator of Wnt signaling, suppresses tumor growth and metastasis in osteosarcoma , 2015, Oncogene.
[2] D. Largaespada,et al. PVT1 dependence in cancer with MYC copy-number increase , 2014, Nature.
[3] Christopher W. Whelan,et al. Genomic organization and evolution of double minutes/homogeneously staining regions with MYC amplification in human cancer , 2014, Nucleic acids research.
[4] Li Ding,et al. Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. , 2014, Cell reports.
[5] N. Caplen,et al. p53-dependent Induction of PVT1 and miR-1204* , 2011, The Journal of Biological Chemistry.
[6] Michael A Choti,et al. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma , 2011, Nature Genetics.
[7] L. You,et al. Genome-wide screen identifies PVT1 as a regulator of Gemcitabine sensitivity in human pancreatic cancer cells. , 2011, Biochemical and biophysical research communications.
[8] K. Janeway,et al. Modeling human osteosarcoma in the mouse: From bedside to bench. , 2010, Bone.
[9] A. Ashworth,et al. A genome-wide association study of Hodgkin Lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21, and 10p14 (GATA3) , 2010, Nature Genetics.
[10] Daniel Birnbaum,et al. Genome profiling of ERBB2-amplified breast cancers , 2010, BMC Cancer.
[11] Hanlee P. Ji,et al. Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. , 2010, Cancer research.
[12] Lawrence A. Donehower,et al. 20 years studying p53 functions in genetically engineered mice , 2009, Nature Reviews Cancer.
[13] L. Donehower,et al. MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression. , 2009, Cancer research.
[14] Lawrence S. Hon,et al. High-resolution analysis of copy number alterations and associated expression changes in ovarian tumors , 2009, BMC Medical Genomics.
[15] F. Alt,et al. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. , 2008, Genes & development.
[16] R. Bajaj,et al. Double-minute MYC amplification and deletion of MTAP, CDKN2A, CDKN2B, and ELAVL2 in an acute myeloid leukemia characterized by oligonucleotide-array comparative genomic hybridization. , 2008, Cancer genetics and cytogenetics.
[17] M. Ladanyi,et al. Cell Cycle Regulator Gene CDC5L, a Potential Target for 6p12-p21 Amplicon in Osteosarcoma , 2008, Molecular Cancer Research.
[18] R. Stephens,et al. The Identification of MicroRNAs in a Genomically Unstable Region of Human Chromosome 8q24 , 2008, Molecular Cancer Research.
[19] N. Caplen,et al. Pvt1-encoded microRNAs in oncogenesis , 2008, Retrovirology.
[20] Wen-Lin Kuo,et al. Amplification of PVT1 Contributes to the Pathophysiology of Ovarian and Breast Cancer , 2007, Clinical Cancer Research.
[21] A. Osterman,et al. Bcl-2 and Bcl-XL Regulate Proinflammatory Caspase-1 Activation by Interaction with NALP1 , 2007, Cell.
[22] Shishir Shah,et al. Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma , 2004, BMC Cancer.
[23] A. Huvos,et al. Frequent amplification and rearrangement of chromosomal bands 6p12‐p21 and 17p11.2 in osteosarcoma , 2004, Genes, chromosomes & cancer.
[24] Michael B. Elowitz,et al. The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[25] J. Wunder,et al. Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma , 2001, Cancer.
[26] M. Kapoor,et al. High metastatic potential in mice inheriting a targeted p53 missense mutation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[27] M. Schwab. Oncogene amplification in solid tumors. , 1999, Seminars in cancer biology.
[28] K. Kinzler,et al. Genetic instabilities in human cancers , 1998, Nature.
[29] R. Romagnoli,et al. Malignant tumors of the osteogenic matrix. , 1998, European Journal of Radiology.
[30] P. Kleihues,et al. Tumors associated with p53 germline mutations: a synopsis of 91 families. , 1997, The American journal of pathology.
[31] A. Zetterberg,et al. Detection of TP53 gene mutations in human sarcomas. , 1995, European journal of cancer.
[32] L. Donehower,et al. Spontaneous and carcinogen–induced tumorigenesis in p53–deficient mice , 1993, Nature Genetics.
[33] D. Pinkel,et al. Comparative Genomic Hybridization for Molecular Cytogenetic Analysis of Solid Tumors , 2022 .
[34] M. Fernö,et al. c‐myc amplification is an independent prognostic factor in postmenopausal breast cancer , 1992, International journal of cancer.
[35] L. Donehower,et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.
[36] A. Palumbo,et al. Human homologue of Moloney leukemia virus integration-4 locus (MLVI-4), located 20 kilobases 3' of the myc gene, is rearranged in multiple myelomas. , 1990, Cancer research.
[37] D. V. Von Hoff,et al. Double minutes arise from circular extrachromosomal DNA intermediates which integrate into chromosomal sites in human HL-60 leukemia cells. , 1990, The Journal of clinical investigation.
[38] B. Spengler,et al. Homogeneously Staining Regions and Double Minute Chromosomes, Prevalent Cytogenetic Abnormalities of Human Neuroblastoma Cells , 1983 .